MIRA INFORM REPORT

 

 

Report Date :

12.11.2013

 

IDENTIFICATION DETAILS

 

Name :

GB PHARMA LTD.

 

 

Registered Office :

65 Chatsworth Road, London, NW2 4BG, London County

 

 

Country :

United Kingdom

 

 

Financials (as on) :

31.03.2012

 

 

Date of Incorporation :

05.03.1992

 

 

Com. Reg. No.:

02694337

 

 

Legal Form :

Private Independent

 

 

Line of Business :

Wholesale of pharmaceutical goods

 

 

No. of Employees :

5

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

Payment Behaviour :

Unknown

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

United Kingdom

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

UNITED KINGDOM - ECONOMIC OVERVIEW

 

The UK, a leading trading power and financial center, is the second largest economy in Europe after Germany. Over the past two decades, the government has greatly reduced public ownership and contained the growth of social welfare programs. Agriculture is intensive, highly mechanized, and efficient by European standards, producing about 60% of food needs with less than 2% of the labor force. The UK has large coal, natural gas, and oil resources, but its oil and natural gas reserves are declining and the UK became a net importer of energy in 2005. Services, particularly banking, insurance, and business services, account by far for the largest proportion of GDP while industry continues to decline in importance. After emerging from recession in 1992, Britain's economy enjoyed the longest period of expansion on record during which time growth outpaced most of Western Europe. In 2008, however, the global financial crisis hit the economy particularly hard, due to the importance of its financial sector. Sharply declining home prices, high consumer debt, and the global economic slowdown compounded Britain's economic problems, pushing the economy into recession in the latter half of 2008 and prompting the then BROWN (Labour) government to implement a number of measures to stimulate the economy and stabilize the financial markets; these include nationalizing parts of the banking system, temporarily cutting taxes, suspending public sector borrowing rules, and moving forward public spending on capital projects. Facing burgeoning public deficits and debt levels, in 2010 the CAMERON-led coalition government (between Conservatives and Liberal Democrats) initiated a five-year austerity program, which aimed to lower London's budget deficit from over 10% of GDP in 2010 to nearly 1% by 2015. In November 2011, Chancellor of the Exchequer George OSBORNE announced additional austerity measures through 2017 because of slower-than-expected economic growth and the impact of the euro-zone debt crisis. The CAMERON government raised the value added tax from 17.5% to 20% in 2011. It has pledged to reduce the corporation tax rate to 21% by 2014. The Bank of England (BoE) implemented an asset purchase program of up to £375 billion (approximately $605 billion) as of December 2012. During times of economic crisis, the BoE coordinates interest rate moves with the European Central Bank, but Britain remains outside the European Economic and Monetary Union (EMU). In 2012, weak consumer spending and subdued business investment weighed on the economy. GDP fell 0.1%, and the budget deficit remained stubbornly high at 7.7% of GDP. Public debt continued to increase

Source : CIA

Company name and address

 

Gb Pharma Ltd.

 

 

 

65 Chatsworth Road

 

 

London, NW2 4BG

United Kingdom

(Trading Address)
Registered Address

Tel:

020 8830 1057

 

www.gbpharma.co.uk

 

Employees:

5

Company Type:

Private Independent

 

 

Quoted Status:

Non-quoted Company

Incorporation Date:

05-Mar-1992

Auditor:

Kaydee Associates Ltd

 

 

 

 

 

 

 

Fiscal Year End:

31-Mar-2012

Reporting Currency:

British Pound Sterling

Annual Sales:

NA

Total Assets:

0.4

 

 

 

 

 

 

Business Description

 

 

Wholesale of pharmaceutical goods.

 

Industry

 

 

Industry

Health and Personal Care Wholesale

ANZSIC 2006:

3720 - Pharmaceutical and Toiletry Goods Wholesaling

ISIC Rev 4:

4649 - Wholesale of other household goods

NACE Rev 2:

4646 - Wholesale of pharmaceutical goods

NAICS 2012:

424210 - Drugs and Druggists' Sundries Merchant Wholesalers

UK SIC 2007:

4646 - Wholesale of pharmaceutical goods

US SIC 1987:

5122 - Drugs, Drug Proprietaries, and Druggists' Sundries

 

 

Key Executives

 

 

 

Name

Title

 

Elzbieta Batra

Secretary

 

Pardeep Batra

Director

 

 

 

 

News

 

 

Title

Date

Equatorial Guinea's [EG] Ministry of Health convenes in Washington, DC with GB Group Global and TNI Biotech OTCBB:TNIB to launch major innovative...
Biotech Week (434 Words)

17-Apr-2013

Equatorial Guinea's [EG] Ministry of Health convenes in Washington, DC with GB Group Global and TNI Biotech (OTCBB:TNIB) to launch major innovative health solutions and improve pharmaceutical quality for its citizens
PR Newswire US (371 Words)

8-Apr-2013

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
NewsRX (121 Words)

23-Nov-2012

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma...
Biotech Week (372 Words)

21-Nov-2012

TNI BioTech, Inc. (TNIB) Enters Exclusive Distributo...
StockHouse USA (413 Words)

15-Nov-2012

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma...
Associated Press (943 Words)

15-Nov-2012

 

Financial Summary

 

 

FYE: 31-Mar-2012

USD (mil)

Key Figures

 

Current Assets

0.39

Fixed Assets

0.0081

Total Liabilities

0.40

Net Worth

0.0024

 

Key Ratios

 

Current Ratio

0.99

Acid Test

0.99

 

 

Registered No.(UK)

 

02694337

 

1 - Profit & Loss Item Exchange Rate: USD 1 = GBP 0.6267523

2 - Balance Sheet Item Exchange Rate: USD 1 = GBP 0.6281078

Corporate Overview

 

 

Location
65 Chatsworth Road
London, NW2 4BG
London County
United Kingdom

 

Tel:

020 8830 1057

 

www.gbpharma.co.uk

Sales GBP(mil):

NA

Assets GBP(mil):

0.3

Employees:

5

Fiscal Year End:

31-Mar-2012

 

 

 

Industry:

Personal and Household Products

Registered Address:
Challenge House
616 Mitcham Road
Croydon, CR0 3AA
United Kingdom

 

Incorporation Date:

05-Mar-1992

Company Type:

Private Independent

Quoted Status:

Not Quoted

Registered No.(UK):

02694337

 

Director:

Pardeep Batra

 

Industry Codes

 

ANZSIC 2006 Codes:

3720

-

Pharmaceutical and Toiletry Goods Wholesaling

 

ISIC Rev 4 Codes:

4649

-

Wholesale of other household goods

 

NACE Rev 2 Codes:

4646

-

Wholesale of pharmaceutical goods

 

NAICS 2012 Codes:

424210

-

Drugs and Druggists' Sundries Merchant Wholesalers

 

US SIC 1987:

5122

-

Drugs, Drug Proprietaries, and Druggists' Sundries

 

UK SIC 2007:

4646

-

Wholesale of pharmaceutical goods

 

Business Description

Wholesale of pharmaceutical goods.

Source: Experian Ltd.

More Business Descriptions

Import and Export Agents

Source: 118 Info

 

 

 

 

 

Financial Data

Financials in:

GBP(mil)

 

Assets:

0.3

Current Assets:

0.2

 

Fixed Assets:

0.0

 

Long Term Debt:

0.0

 

Total Liabilities:

0.2

 

Issued Capital:

0.0

 

Working Capital:

0.0

 

Net Worth:

0.0

 

 

 

Date of Financial Data:

31-Mar-2012

 

1 Year Growth

NA

 

Key Corporate Relationships

Auditor:

Kaydee Associates Ltd

Bank:

The Royal Bank Of Scotland PLC

 

Auditor:

Kaydee Associates Ltd

 

Auditor History

Kaydee Associates Ltd

31-Mar-2012

Kaydee Associates Ltd

31-Mar-2011

Kaydee Associates

31-Mar-2010

Kaydee Associates

31-Mar-2009

Kaydee Associates

31-Mar-2008

 

 

 

 

 

 

 

 

 

 

Gb Pharma Ltd.

London, , United Kingdom, Tel: 020 8830 1057, URL: http://www.gbpharma.co.uk

 

Executives Report

 

Board of Directors

 

Name

Title

Function

 

Pardeep Batra

 

Director

Director/Board Member

 

Age: 55

 

 

Executives

 

Name

Title

Function

 

Elzbieta Batra

 

Secretary

Company Secretary

 

Age: 51

 

 

 

Directors and Shareholders Report

 

Main Office Address:
65 Chatsworth Road
London
United Kingdom NW2 4BG

Tel: 020 8830 1057
URL: http://www.gbpharma.co.uk

Annual Return Date: 05 Mar 2013

 

Individual Directors

 

Name

Status

DOB

Filed Address

Appointment Date

Resignation Date

Summary of Directorships

 

Pardeep
Batra

Current

16 Feb 1958

65 Chatsworth Road, Brondesbury,
London , London NW2 4BG

05 Feb 2000

NA

Current:1
Previous:1
Disqualifications:0

 

Elzbieta
Batra

Previous

05 Sep 1962

65 Chatsworth Road, Bondesbury,
London , London NW2 4BG

02 Mar 1992

31 Oct 2002

Current:1
Previous:1
Disqualifications:0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate Directors

 

There are no corporate directors for this company.

 

 

Individual Secretaries

 

Name

Status

DOB

Filed Address

Appointment Date

Resignation Date

Summary of Directorships

 

Elzbieta
Batra

Current

05 Sep 1962

65 Chatsworth Road, Bondesbury,
London , London NW2 4BG

31 Oct 2002

NA

Current:1
Previous:1
Disqualifications:0

 

Pardeep
Batra

Previous

16 Feb 1958

65 Chatsworth Road, Brondesbury,
London , London NW2 4BG

02 Mar 1992

31 Oct 2002

Current:1
Previous:1
Disqualifications:0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate Secretaries

 

There are no corporate secretaries for this company.

 

 

Individual Shareholders

 

Name

Share Details
(As Reported)

Share Type

# of Shares

Share Price (GBP)

Share Value (GBP)

% of Total Shares

Elzbieta Batra

1 Ordinary GBP 1.00

Ordinary

1

1.00

1.00

50.00

Pardeep Batra

1 Ordinary GBP 1.00

Ordinary

1

1.00

1.00

50.00

 

 

 

 

 

 

 

 

Corporate Shareholders

 

There are no corporate shareholders for this company.

 

 

 

 

 

News

 

 

Equatorial Guinea's [EG] Ministry of Health convenes in Washington, DC with GB Group Global and TNI Biotech OTCBB:TNIB to launch major innovative...
Biotech Week (434 Words)

17-Apr-2013

 

 

Equatorial Guinea's [EG] Ministry of Health convenes in Washington, DC with GB Group Global and TNI Biotech (OTCBB:TNIB) to launch major innovative health solutions and improve pharmaceutical quality for its citizens
PR Newswire US (371 Words)

08-Apr-2013

 

 

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
NewsRX (121 Words)

23-Nov-2012

 

 

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma...
Biotech Week (372 Words)

21-Nov-2012

 

 

TNI BioTech, Inc. (TNIB) Enters Exclusive Distributo...
StockHouse USA (413 Words)

15-Nov-2012

 

 

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma...
Associated Press (943 Words)

15-Nov-2012

 

 

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
PR Newswire US (825 Words)

15-Nov-2012

 



Gb Pharma Ltd.

 

London, United Kingdom, Tel: 020 8830 1057, URL: http://www.gbpharma.co.uk

Annual Profit & Loss

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

 

 

 

 

31-Mar-2012

31-Mar-2011

31-Mar-2010

31-Mar-2009

31-Mar-2008

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate (Period Average)

0.626752

0.643394

0.627794

0.592803

0.498361

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Depreciation

0.0

0.0

0.0

0.0

0.0

 

 

 

Annual Balance Sheet

Financials in: USD (mil)

 

 

 

31-Mar-2012

31-Mar-2011

31-Mar-2010

31-Mar-2009

31-Mar-2008

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate

0.628108

0.62385

0.659239

0.697666

0.503145

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Total Tangible Fixed Assets

0.0

0.0

0.0

0.0

0.0

Intangible Assets

0.0

0.0

0.0

0.0

0.0

Investments

0.0

0.0

0.0

0.0

0.0

Total Fixed Assets

0.0

0.0

0.0

0.0

0.0

Stocks

0.0

-

0.0

0.0

0.0

Work in Progress

0.0

-

0.0

0.0

0.0

Total Stocks Work In Progress

0.0

0.1

0.0

0.0

0.0

Total Debtors

0.2

0.9

0.2

0.2

0.7

Cash and Equivalents

0.2

0.1

0.4

0.1

0.1

Other Current Assets

0.0

0.0

0.0

0.0

0.0

Total Current Assets

0.4

1.1

0.5

0.4

0.8

Total Assets

0.4

1.1

0.5

0.4

0.8

Other Current Liabilities

0.4

1.1

0.5

0.4

0.8

Total Current Liabilities

0.4

1.1

0.5

0.4

0.8

Group Loans (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Director Loans (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Hire Purchase (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Leasing (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Total Hire Purchase Loans (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Other Long Term Loans

0.0

0.0

0.0

0.0

0.0

Accruals/Deferred Income (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Other Long Term Liabilities

0.0

0.0

0.0

0.0

0.0

Total Long Term Liabilities

0.0

0.0

0.0

0.0

0.0

Deferred Taxation

0.0

0.0

0.0

0.0

0.0

Other Provisions

0.0

0.0

0.0

0.0

0.0

Total Provisions

0.0

0.0

0.0

0.0

0.0

Issued Capital

0.0

0.0

0.0

0.0

0.0

Share Premium Accounts

0.0

0.0

0.0

0.0

0.0

Revaluation Reserve

0.0

0.0

0.0

0.0

0.0

Retained Earnings

0.0

0.0

0.0

0.0

0.0

Other Reserves

0.0

0.0

0.0

0.0

0.0

Minority Interests (Balance Sheet)

0.0

0.0

0.0

0.0

0.0

Total Shareholders Funds

0.0

0.0

0.0

0.0

0.0

Net Worth

0.0

0.0

0.0

0.0

0.0

 

 

 

Annual Cash Flows

Financials in: USD (mil)

 

 

 

31-Mar-2012

31-Mar-2011

31-Mar-2010

31-Mar-2009

31-Mar-2008

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate (Period Average)

0.626752

0.643394

0.627794

0.592803

0.498361

Consolidated

No

No

No

No

No

 

 

 

 

 

 

 

 

 

Annual Ratios

Financials in: USD (mil)

 

 

 

31-Mar-2012

31-Mar-2011

31-Mar-2010

31-Mar-2009

31-Mar-2008

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate

0.628108

0.62385

0.659239

0.697666

0.503145

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Current Ratio

0.99

1.00

0.99

0.99

1.00

Liquidity Ratio

0.99

0.89

0.99

0.99

1.00

Equity Gearing

60.00%

8.00%

9.00%

21.00%

24.00%

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.63.29

UK Pound

1

Rs.101.36

Euro

1

Rs.84.59

 

 

INFORMATION DETAILS

 

Report Prepared by :

PDT

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.